CervoMed releases clinical data supporting neflamapimod for DLB
CervoMed released new analyses from its Phase 2b trial reinforcing neflamapimod's efficacy. The data supports selecting the 50 mg dose for Phase 3, enhancing investor confidence in the company's dementia pipeline.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed